Prucalopride is effective in patients with severe Chronic constipation in whom laxatives fail to provide adequate relief: Results of a double-blind, placebo-controlled clinical trialCOREMANS, Georges; KERSTENS, René; DE PAUW, Martine et al.Digestion. 2003, Vol 67, Num 1-2, pp 82-89, issn 0012-2823, 8 p.Article

Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1-Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE TrialsTEBAS, Pablo; SENSION, Michael; ARRIBAS, José et al.Clinical infectious diseases. 2014, Vol 59, Num 3, pp 425-434, issn 1058-4838, 10 p.Article

96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trialsRIMSKY, Laurence; VAN EYGEN, Veerle; HOOGSTOEL, Annemie et al.Antiviral therapy (London). 2013, Vol 18, Num 8, pp 967-977, issn 1359-6535, 11 p.Article

Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteersCRAUWELS, Herta M; VAN HEESWIJK, Rolf P. G; BUELENS, Annemie et al.International journal of clinical pharmacology and therapeutics. 2014, Vol 52, Num 2, pp 118-128, issn 0946-1965, 11 p.Article

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsNELSON, Mark; AMAYA, Gerardo; VANVEGGEL, Simon et al.Journal of antimicrobial chemotherapy (Print). 2012, Vol 67, Num 8, pp 2020-2028, issn 0305-7453, 9 p.Article

Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less: week 48 phase III analysisMOLINA, Jean-Michel; CLUMECK, Nathan; PEDANT, Karla et al.AIDS (London). 2013, Vol 27, Num 6, pp 889-897, issn 0269-9370, 9 p.Article